Skip to main content

Month: May 2021

Skylight Health Announces $12 Million Bought Deal Public Offering of Common Shares

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES NOR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, May 18, 2021 (GLOBE NEWSWIRE) — Skylight Health Group Inc. (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, is pleased to announce that it has entered into an agreement with Raymond James Ltd., as sole bookrunner and co-lead underwriter and Stifel GMP as co-lead underwriter on behalf of a syndicate of underwriters (collectively the “Underwriters”) pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 8,572,000 common shares of the Company (“Common Shares”) at a price of $1.40 per Common Share for gross proceeds of approximately $12 million...

Continue reading

Wind farm Wind Wall 1 successfully completed and delivered to Cubico

Hässleholm, Sweden, May 18th, 2021 Eolus has completed the construction of the repower of wind farm Wind Wall 1 located near Tehachapi, California, USA. All conditions for the completion of the transaction between Eolus and Cubico regarding the establishment of the wind farm comprising 46.5 MW have been fulfilled and the buyer has taken over the facility. In October 2020, Wind Wall Development LLC, fully owned by Eolus subsidiary Eolus North America, Inc., signed an agreement with Cubico Sustainable Investments (Cubico) regarding the sale of Wind Wall 1 comprising 13 wind turbines of the model Vestas126, of which 11 have a capacity of 3.6 MW and 2 have a capacity of 3.45 MW. All conditions for the completion of the transaction regarding the wind farm have been fulfilled and payment has occurred. Eolus will provide asset management services...

Continue reading

Titanium Transportation Group Declares Quarterly Dividends

BOLTON, Ontario, May 18, 2021 (GLOBE NEWSWIRE) — The Board of Directors of Titanium Transportation Group Inc. (“Titanium” or the “Company”) (TSX VENTURE:TTR) has declared a quarterly dividend of $0.02 per common share, payable on June 15, 2021 to shareholders of record at the close of business on May 31, 2021. The amount of the dividend is consistent with the March 15, 2021 dividend. About Titanium Titanium is a leading asset-based transportation and logistics company servicing Canada and the United States, with approximately 800 power units, 3,000 trailers and 1,100 employees and independent owner operators. Titanium provides truckload, dedicated, and cross-border trucking services, freight logistics, and warehousing and distribution to over 1,000 customers. In February 2021, Titanium completed its strategic acquisition of International...

Continue reading

FRO – Acquisition of Six VLCCs Under Construction

Frontline Ltd. (NYSE and OSE: FRO) (“Frontline” or the “Company”) today announces that it has entered into an agreement for the acquisition through resale of six latest generation ECO-type VLCC newbuilding contracts. The six VLCCs are currently under construction at the Hyundai Heavy Industries (“HHI”) shipyard in South Korea and are being acquired for an aggregate purchase price of $565.8 million, including an estimated $25.7 million in additions and upgrades to the standard specifications. The vessels are designed to operate on different fuels, including Biofuel, have the potential to be converted or retrofitted to consume fuel like LNG or Ammonia and consequently there is an ability to cut CO2 emissions to zero when technology, logistics and the regulatory framework allows for it. The newbuildings will also be fitted with Exhaust Gas...

Continue reading

Teladoc Health to Participate in William Blair Growth Stock Conference

PURCHASE, NY, May 18, 2021 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that Jason Gorevic, chief executive officer, and Mala Murthy, chief financial officer, will participate in the William Blair Growth Stock Conference on June 1, 2021, at 1:40 p.m. ET. A live audio webcast and replay of the presentation will be available at http://ir.teladochealth.com/news-and-events/events-and-presentations/. About Teladoc HealthTeladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health...

Continue reading

STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year

Fourth quarter revenue increases 6% as reported; full year increases 3% as reported Full year earnings per diluted share of $4.63 on a U.S. GAAP basis and $6.17 on an adjusted basis on effective tax rates of 23.3% and 20.7%, respectively Company provides outlook for fiscal 2022 including Cantel MedicalDUBLIN, IRELAND, May 18, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021. Revenue as reported for the quarter increased 6% to $873.5 million compared with $823.0 million in the fourth quarter of fiscal 2020, with growth in all three segments. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 0.3% for the fourth quarter of fiscal 2021 as compared to constant currency organic revenue results...

Continue reading

Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays

SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its potency assays for lifileucel. Previously, the company reported the submission of assay data to the FDA and recently the FDA provided comments regarding the data package. Following FDA feedback, Iovance will continue its ongoing work developing and validating its potency assays and plans to submit additional assay data and to meet with the FDA in the second half of 2021. The company’s biologics license application (BLA) submission for lifileucel is now expected to occur during the first half of 2022. “TIL is a first-in-class, one-time...

Continue reading

Intertape Polymer Group Announces Pricing of USD$400 Million 4.375% Senior Unsecured Notes

MONTREAL and SARASOTA, Fla., May 18, 2021 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (“IPG” or “the Company”) announced today the pricing of its offering of USD$400 million 4.375% senior unsecured notes due in 2029 (the “Offering”). These notes will be issued at par pursuant to a note indenture to be entered into with Regions Bank, as trustee, at the closing of the Offering. The Company anticipates that the closing of the Offering will occur on or about June 8, 2021. The Company intends to use the net proceeds from the Offering to redeem its currently outstanding USD$250 million 7.00% senior unsecured notes which are scheduled to mature on October 15, 2026 (the “Existing Notes”), to repay a portion of the borrowings outstanding under its existing five-year, USD$600 million credit facility...

Continue reading

Atico Reports Financial Results for First Quarter of 2021

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 18, 2021 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the three months ended March 31, 2021 (“Q1-2021”), posting income from mining operations of $5.3 million and a net income of $1.2 million. Fernando E. Ganoza, CEO and Director, commented, “This was a particularly challenging quarter given the operational setbacks resulting in loss production and an increase in cash cost, partially mitigated by higher realized metal prices leading to a cash margin of $2.38 per pound of payable copper. The Company closed the quarter showing a strong cash position of US$ 9.2 million and US$ 18 million in trade receivables, which were mostly realized in...

Continue reading

First Eagle Alternative Capital BDC, Inc. Prices Public Offering of 5.00% Notes due 2026

BOSTON, May 18, 2021 (GLOBE NEWSWIRE) — First Eagle Alternative Capital BDC, Inc. (NASDAQ: FCRD) (“First Eagle Alternative Capital BDC” or the “Company”) announced that it priced a public offering of $60,000,000 aggregate principal amount of 5.00% Notes due 2026 (the “Notes”). The Notes will mature on May 25, 2026 and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after May 25, 2023. The Notes will bear interest at a rate of 5.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, beginning September 30, 2021. The Company also granted the underwriters a 30-day option to purchase up to an additional $9,000,000 in aggregate principal amount of Notes to cover overallotments, if any. The Company expects to list the Notes on the New York Stock...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.